The use of biological agents in the treatment of rheumatoid arthritis

35Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

Abstract

Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently. Pharmacological treatment should not just comprise anti-inflammatory agents and corticosteroids. The current therapeutic approach is to start a disease modifying agent early in the illness to prevent eventual joint damage. Older disease modifying anti-rheumatic drugs (DMARDs) include methotrexate, sulphasalazine and hydroxychloroquine. Newer ones such as leflunomide and cyclosporine are also used. A recent advance in the management of rheumatoid arthritis is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumour necrosis factor (TNF)-blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept. Other agents which are in development include anti-IL6 tocilizumab, anti-CD22 and anti-lymphostat B. In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed.

Author supplied keywords

Cite

CITATION STYLE

APA

Fan, P. T., & Leong, K. H. (2007). The use of biological agents in the treatment of rheumatoid arthritis. Annals of the Academy of Medicine Singapore. Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.v36n2p128

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free